Variable | N (%) |
---|---|
Comorbids | |
HTN | 60 (24.0) |
T2DM | 37 (14.8) |
CVD | 4 (1.6) |
Smoking status | |
Current smoker | 15 (6.0) |
Ex-smoker | 22 (8.8) |
Never smoked | 212 (85.2) |
Smokeless tobacco use | |
Current user | 7 (2.8) |
Ex-user | 20 (8.0) |
Never used | 223 (89.2) |
Tumor type | |
Glioma | 117 (46.8) |
Meningioma | 53 (21.2) |
Schwannoma | 12 (4.8) |
Pituitary | 44 (17.6) |
Others | 24 (9.6) |
Surgical intervention | |
Excisional biopsy | 195 (78.0) |
Total resection after diagnostic biopsy | 11 (4.4) |
Multiple interventions | 27 (10.8) |
No surgical interventions | 17 (6.8) |
Adjuvant therapy | |
Chemotherapy | 11 (4.4) |
Radiotherapy | 24 (9.6) |
Combination | 63 (25.2) |
No adjuvant therapy | 152 (60.8) |
Status of cancer treatment | |
Completed | 112 (44.8) |
Ongoing | 138 (55.2) |
Feeding tube needed | 2 (0.8) |
Tracheostomy needed | 1 (0.4) |
Urinary catheter needed | 5 (2.0) |
Social support | |
≤ 18 (Low social support) | 6 (2.4) |
> 18 (High social support) | 244 (97.6) |
Depression | |
0–7 (Normal) | 225 (90.0) |
8–10 (Mild depression) | 14 (5.6) |
11–21 (Symptomatic depression) | 11 (4.4) |
Anxiety | |
0–7 (Normal) | 229 (91.6) |
8–10 (Mild anxiety) | 16 (6.4) |
11–21 (Symptomatic anxiety) | 5 (2.0) |